Common and Rare Ocular Side-effects of the Dexamethasone Implant

REFERENCES

• Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134–1146.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–1914.
   Google Scholar
• Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545–553.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Fernandez-Sanz G, Bala S, et al. Desegmentation of Ozurdex implant in vitreous cavity: report of two cases. Br J Ophthalmol. 2014;98:961–963.
   Google Scholar
• Donmez O, Parlak M, Yaman A, et al. Splitting of a Dexamethasone implant (Ozurdex) following the injection. Case Rep Ophthalmol Med. 2013;2013:247949.
   PubMedGoogle Scholar
• Chalioulias K, Muqit MM. Vitreoretinal surgery for inadvertent intralenticular Ozurdex implant. Eye (Lond). 2014;28:1523–1524.
   PubMed Web of Science ®Google Scholar
• Chhabra R, Kopsidas K, Mahmood S. Accidental insertion of dexamethasone implant into the crystalline lens – 12 months follow-up. Eye. 2014;28:624–625.
   PubMed Web of Science ®Google Scholar
• Coca-Robinot J, Casco-Silva B, Armada-Maresca F, et al. Accidental injections of dexamethasone intravitreal implant (Ozurdex) into the crystalline lens. Eur J Ophthalmol. 2014;24:633–636.
   PubMed Web of Science ®Google Scholar
• Fasce F, Battaglia Parodi M, Knutsson KA, et al. Accidental injection of dexamethasone intravitreal implant in the crystalline lens. Acta Ophthalmologica. 2014;92:e330–e331.
   PubMed Web of Science ®Google Scholar
• Panjaphongse R, Stewart JM. Risk factors for wound leakage after Ozurdex injection. Ocul Immunol Inflamm. 2015;23:410–411.
   PubMed Web of Science ®Google Scholar
• Khurana RN, Appa SN, McCannel CA, et al. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. Ophthalmology. 2014;121:67–71.
   PubMed Web of Science ®Google Scholar
• Pardo-Lopez D, Frances-Munoz E, Gallego-Pinazo R, et al. Anterior chamber migration of dexamethasone intravitreal implant (Ozurdex®). Graefes Arch Clin Exp Ophthalmol. 2012;250:1703–1704.
   Google Scholar
• Vela JI, Crespí J, Andreu D. Repositioning of dexamethasone intravitreal implant (Ozurdex) migrated into the anterior chamber. Int Ophthalmol. 2012;32:583–584.
   PubMedGoogle Scholar
• Kishore SA, Schaal S. Management of anterior chamber dislocation of dexamethasone implant. Ocul Immunol Inflamm. 2013;21:90–91.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121:2473–2481.
   PubMed Web of Science ®Google Scholar
• Kiddee W, Trope GE, Sheng L, et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol. 2013;58:291–310.
   PubMed Web of Science ®Google Scholar
• Capone A, Singer MA, Dodwell DG, et al. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina. 2014;34:342–351.
   PubMed Web of Science ®Google Scholar
• Ozkok A, Saleh OA, Sigford D, et al. The OMAR Study: comparison of Ozurdex and triamcinolone acetonide for refractory cystoid macular edema in retinal vein occlusion. Retina. 2015;35:1393–1400.
   PubMed Web of Science ®Google Scholar
• Callanan DG, Gupta S, Boyer DS, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. The PLACID Study Group. Ophthalmology. 2013;120:1843–1851.
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Goldstein M, Maturi RK, et al. Dexamethasone intravitreal implant as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration: A multicenter randomized controlled trial. Ozurdex® ERIE Study Group. Ophthalmologica. 2015;234:40–54.
   PubMed Web of Science ®Google Scholar
• Ramu J, Yang Y, Menon G, et al. A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study). Eye (Lond). 2015;29:1603–1612.
   Google Scholar
• Casati S, Bruni E, Marchini G. Retinal and vitreous hemorrhage after traumatic impact of dexamethasone implant in a vitrectomized eye. Eur J Ophthalmol. 2016;26:e55–e57.
   PubMed Web of Science ®Google Scholar
• Afshar AR, Loh AR, Pongsachareonnont P, et al. Dexamethasone intravitreal implant trapped at the macula in a silicone oil-filled eye. Ophthalmology. 2013;120:2748–2749.
   PubMed Web of Science ®Google Scholar
• Noma H, Funatsu H, Mimura T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology. 2009;116:87–93.
   PubMed Web of Science ®Google Scholar
• Praidou A, Klangas I, Papakonstantinou E, et al. Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. Curr Eye Res. 2009;34:152–161.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Omar AF. Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion. J Ocul Pharmacol Ther. 2012;28:547–549.
   PubMed Web of Science ®Google Scholar
• Panjaphongse R, Stewart JM. Vitreomacular traction after dexamethasone intravitreal implant (Ozurdex) injection: the effect of anomalous posterior vitreous detachment. Retin Cases Brief Rep. 2016;10:55–57.
   PubMedGoogle Scholar
• Arikan Yorgun M, Mutlu M, Toklu Y, et al. Suspected bacterial endophthalmitis following sustained-release dexamethasone intravitreal implant: a case report. Korean J Ophthalmol. 2014;28:275–277.
   PubMedGoogle Scholar
• Marchino T, Vela JI, Bassaganyas F, et al. Acute-onset endophthalmitis caused by alloiococcus otitidis following a dexamethasone intravitreal implant. Case Rep Ophthalmol. 2013;4:37–41.
   PubMedGoogle Scholar
• Esen E, Sizmaz S, Demircan N. Two cases of acute endophthalmitis after intravitreal dexamethasone implant injection. Retin Cases Brief Rep. 2016;10:154–156.
   PubMedGoogle Scholar
• Lei S, Lam WC. Efficacy and safety of dexamethasone intravitreal implant for refractory macular edema in children. Can J Ophthalmol. 2015;50:236–241.
   PubMed Web of Science ®Google Scholar
• Sella R, Oray M, Friling R, et al. Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis. Graefes Arch Clin Exp Ophthalmol. 2015;253:1777–1782.
   Google Scholar
• Tomkins-Netzer O, Talat L, Seguin Greenstein S, et al. Outcome of treating pediatric uveitis with dexamethasone implants. Am J Ophthalmol. 2015;161:110–115.
   PubMed Web of Science ®Google Scholar